Effect of Treatment on the Evolution of Renal Abnormalities in Lupus Nephritis

New England Journal of Medicine

Volumn 311, Issue 8, 1984, Pages 491-495

  Balow, James E ^a,b   Austin, Howard A ^a,b   Muenz, Larry R ^a,b   Joyce, Kathleen M ^a,b   Antonovych, Tatiana T ^a,b   Klippel, John H ^a,b   Steinberg, Alfred D ^a,b   Plotz, Paul H ^a,b   Decker, John L ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; PREDNISONE;

CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSIS; DRUG THERAPY; ETIOLOGY; HISTOLOGY; HUMAN; KIDNEY; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY;

EID: 0021137695     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198408233110802     Document Type: Article

References (30)

1. Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 1974; 17: 923–37.
2. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 113. 51–5.
3. Dinanl HJ, Decker JL, Klippcl JH, Balow JE, Plotz PH. Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 1982; 96: 724. 8–36.
4. Carette S, Klippel JH, Decker JL, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis: a long-term follow-up. Ann Intern Med 1983; 995: 1–8.
5. Austin HA IeI, Mucnz LR. Joycet KM. et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983; 75: 386. 2–91.i
6. Donadio JV Jr, Holley KE, Wagoner RD. Ferguson RH, McDuffie FC. Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum 1974; 17: 573–81.
7. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med 1975; 83: 597–605.
8. Decker JL. Klippel JH, Plotz PH, Steinberg AD. Cyclophosphamide or azathioprine in lupus glomerulonephritis: a controlled trial: results at 28 months. Ann Intern Med 1975; 83: 606–15.
9. Cohen AS, Reynolds WE, Franklin EC, et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971; 21: 643–8.
10. Pirani CL, Salinas-Madrigal L. Evaluation of percutaneous renal biopsy, Pathol Annu 1968; 3: 249–96.
11. Churg J, Sobin LU. Renal disease: classification and atlas of glomerular diseases. Tokyo: Igaku-Shoin, 1982.
12. Austin MA III, Muenz LR, Joyce KM, Antonovych IT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689–95.
13. Morel-Maroger L, Méry J-P, Droz D, et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol 1976; 6: 79–118.
14. Pirani CL, Pollack VE, Schwartz FD. The reproducibility of semiquantitative analyses of renal histology. Nephron 1964; 1: 230–7.
15. Donadio JV Jr, Holley KE, Wagoner RD, Ferguson RH. McDuffie FC. Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine, Ann Intern Med 1972; 77: 829–35,
16. Hull CH, Nie NH. SPSS update 7–9. New York: McGraw-Hill. 1981:94–121.
17. Miller RG Jr. Simultaneous statistical inference. New York: McGraw-Hill, 1966:81–7.
18. Draper NR. Smith H. Applied regression analysis. 2nd ed. New York: John Wiley, 1981.
19. Graybill FA. Theory and applications of the linear model, Boston: PWS Publications, 1976:158–62.
20. Baldwin DS, Gluck MC. Lowenstein J, Gallo GR. Lupus nephritis: clinical course as related to morphologic forms and their transitions, Am J Med 1977; 62: 12–30.
21. Pollak VE. Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964; 63: 537–50.
22. Striker GE, Kelly MR, Quadracci LJ, Scribner BH. The course of lupus nephritis: a clinical-pathological correlation of fifty patients, In: Kincaid-Smith P. Mathew TH, Becker EL, eds. Glomerulonephritis: morphology, natural history, and treatment. New York: John Wiley. 1973:1141–66.
23. Appel GB, Silva FG, Pirani CL, Meltzer JI, Estes D. Renal Involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57: 371–410.
24. Cameron JS, Turner DR, Ogg CS, et al. Systemic lupus with nephritis: a long-term study. Q J Med 1979; 48: 1–24.
25. Whiting-O'Keefe Q, Henke JE, Shearn MA, Hopper J Jr. Biava CG, Epstein WV. The information content from renal biopsy in systemic lupus erythematosus: stepwise linear regression analysis. Ann Intern Med 1982; 96: 718–23.
26. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307: 652–9.
27. Cathcart ES, Idelson HA, Seheinberg MA, Couser WG, Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative lupus nephritis. Lancet 1976; 1: 163–6.
28. Liebling MR, McLaughlin K, Hoonsue S, Kasdin J, Barnett EV. Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol 1982; 9: 543–8.
29. Ponticelli C, Zucchelli P, Banfi G, et al. Treatment of diffuse proliferative lupus nephritis by intravenous high-dose methylprednisolone. Q J Med 1982; 51: 16–24.
30. Klippel JH, Austin HA, LeRiche NGH, Balow JE, Decker JL. Immunosuppressive therapy of lupus nephritis, abstract. Ann Rheum Dis 1984; 43: 121.